Evaxion Biotech A/S (EVAX): Price and Financial Metrics
GET POWR RATINGS... FREE!
EVAX Stock Price Chart Interactive Chart >
EVAX Price/Volume Stats
|Current price||$1.90||52-week high||$25.04|
|Prev. close||$1.89||52-week low||$1.51|
|Day high||$2.00||Avg. volume||272,775|
|50-day MA||$2.66||Dividend yield||N/A|
|200-day MA||$4.81||Market Cap||44.09M|
Evaxion Biotech A/S (EVAX) Company Bio
Evaxion Biotech A/S operates as a biotechnology company. The Company develops AI-immunology platform for decoding human immune system to discover and develop immunotherapies for cancer and infectious diseases treatment. Evaxion Biotech serves patients in Denmark.
Most Popular Stories View All
EVAX Latest News Stream
|Loading, please wait...|
EVAX Latest Social Stream
View Full EVAX Social Stream
Latest EVAX News From Around the Web
Below are the latest news stories about Evaxion Biotech A that investors may wish to consider to help them evaluate EVAX as an investment opportunity.
Good morning, trader!
Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck
COPENHAGEN, Denmark, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a paper on personalized therapy with EVX-01 in patients with metastatic melanoma in the open access, peer-reviewed journal OncoImmunology. The paper, entitled, “Personalized therapy with peptide-based neo
After losing some value lately, a hammer chart pattern has been formed for Evaxion Biotech AS Sponsored ADR (EVAX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
- Solidified Nasdaq position as the leading European listings hub with 219 new equity listings, including a record number of 174 initial public offerings (IPOs), raising a total of EUR 13.4 billion- Retail inflow and large interest in SME trading spurred all-time high levels in equity and derivative trading- Continued to lead in ESG with venture investment in Puro.earth and new product launches STOCKHOLM, Sweden, Jan. 21, 2022 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) announced today that Nasdaq
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
COPENHAGEN, Denmark, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today it has received clearance from the Australia Therapeutic Goods Administration to initiate a Phase 2b trial of its patient specific cancer immunotherapy EVX-01 in combination with Merck & Co., Inc.’s (known as MSD outside th
EVAX Price Returns